(Q44171101)

30 November 2017

title

Characterization of anti-natalizumab antibodies in multiple sclerosis patients (English)

1 reference

30 November 2017

0 references

1 reference

5

T Olsson

1 reference

30 November 2017

M Lundkvist

1

1 reference

30 November 2017

E Engdahl

2

1 reference

30 November 2017

C Holmén

3

1 reference

30 November 2017

R Movérare

4

1 reference

30 November 2017

J Hillert

6

1 reference

30 November 2017

A Fogdell-Hahn

7

1 reference

30 November 2017

publication date

8 October 2012

1 reference

Multiple Sclerosis Journal

30 November 2017

published in

1 reference

30 November 2017

volume

19

1 reference

30 November 2017

issue

6

1 reference

30 November 2017

page(s)

757-764

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Human immune response to recombinant human proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Unusual results from immunoassays and the role of the clinical endocrinologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512462920

21 January 2018

Identifiers

DOI

10.1177/1352458512462920

1 reference

30 November 2017

1 reference